Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis - PubMed (original) (raw)
Review
doi: 10.1016/j.eururo.2013.01.012. Epub 2013 Jan 31.
RenJie Zhang, ZuYao Yang, Jack Lee, YaLi Liu, JinHui Tian, XiWen Qin, ZhengJia Ren, Hong Ding, Qing Chen, Chen Mao, JinLing Tang
Affiliations
- PMID: 23395275
- DOI: 10.1016/j.eururo.2013.01.012
Review
Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis
JinQiu Yuan et al. Eur Urol. 2013 May.
Abstract
Context: Phosphodiesterase type 5 inhibitors (PDE5-Is) are currently the first-line therapy for erectile dysfunction (ED), but available studies investigating the comparative effects of different PDE5-Is are limited.
Objective: To compare the efficacy and safety of different classes of oral PDE5-Is for ED.
Evidence acquisition: A systematic search was performed in PubMed, Cochrane Library, and Embase to identify randomized controlled trials that compared different PDE5-Is or PDE5-Is with a placebo for ED. The methodological quality of included studies was appraised with the Cochrane Collaboration bias appraisal tool, and the quality of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation system.
Evidence synthesis: A total of 118 trials (31 195 individuals) were included. There was no major difference in the results between the traditional meta-analysis and the network meta-analysis. Network meta-analysis demonstrated that PDE5-Is were superior to placebo to improve erectile function. Compared with tadalafil (relative risk [RR]: 0.61; 95% confidence interval [CI], 0.33-0.90) and vardenafil (RR: 0.63; 95% CI, 0.35-0.92), avanafil was less effective on Global Assessment Questionnaire question 1. Tadalafil was more effective than vardenafil (mean difference [MD]: 1.49; 95% CI, 0.50-2.50) and udenafil (MD: -1.84; 95% CI, -3.31 to -0.33) as measured by the erectile function domain of the International Index of Erectile Function. For all efficacy outcomes, the absolute effects and the rank tests indicated that tadalafil and vardenafil were the most effective agents. After adjusting for dosage, the conclusion remained the same. Safety analysis showed there was no major difference among different agents.
Conclusions: In recommended doses, oral PDE5-Is are more effective than placebo for ED, and tadalafil seems to be the most effective agent, followed by vardenafil. PDE5-Is are generally safe and well tolerated, and there is no major difference on the safety profile.
Copyright © 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Comment in
Similar articles
- A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy.
Kim ED, Seftel AD, Goldfischer ER, Ni X, Burns PR. Kim ED, et al. J Sex Med. 2014 Mar;11(3):820-30. doi: 10.1111/jsm.12253. Epub 2013 Jul 10. J Sex Med. 2014. PMID: 23841532 Clinical Trial. - Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
Kim E, Seftel A, Goldfischer E, Baygani S, Burns P. Kim E, et al. Curr Med Res Opin. 2015 Feb;31(2):379-89. doi: 10.1185/03007995.2014.989317. Epub 2014 Dec 2. Curr Med Res Opin. 2015. PMID: 25455432 Clinical Trial. - SOP conservative (medical and mechanical) treatment of erectile dysfunction.
Porst H, Burnett A, Brock G, Ghanem H, Giuliano F, Glina S, Hellstrom W, Martin-Morales A, Salonia A, Sharlip I; ISSM Standards Committee for Sexual Medicine. Porst H, et al. J Sex Med. 2013 Jan;10(1):130-71. doi: 10.1111/jsm.12023. J Sex Med. 2013. PMID: 23343170 Review. - Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
Wang R, Burnett AL, Heller WH, Omori K, Kotera J, Kikkawa K, Yee S, Day WW, DiDonato K, Peterson CA. Wang R, et al. J Sex Med. 2012 Aug;9(8):2122-9. doi: 10.1111/j.1743-6109.2012.02822.x. Epub 2012 Jul 3. J Sex Med. 2012. PMID: 22759639 - Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients.
Lombardi G, Macchiarella A, Cecconi F, Del Popolo G. Lombardi G, et al. J Sex Med. 2009 May;6(5):1248-58. doi: 10.1111/j.1743-6109.2008.01205.x. Epub 2009 Feb 9. J Sex Med. 2009. PMID: 19210710 Review.
Cited by
- Development and Ex-Vivo Skin Permeation of Sildenafil Citrate Microemulsion System for Transdermal Delivery.
Jamali N, Moghimipour E, Nikpour F, Salimi A. Jamali N, et al. Iran J Pharm Res. 2024 Mar 28;23(1):e139381. doi: 10.5812/ijpr-139381. eCollection 2024 Jan-Dec. Iran J Pharm Res. 2024. PMID: 39140102 Free PMC article. - New approaches for treating atrial fibrillation: Focus on autonomic modulation.
Sohinki D, Stavrakis S. Sohinki D, et al. Trends Cardiovasc Med. 2020 Oct;30(7):433-439. doi: 10.1016/j.tcm.2019.10.009. Epub 2019 Oct 31. Trends Cardiovasc Med. 2020. PMID: 31708408 Free PMC article. Review. - A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction.
Hansen SA, Aas E, Solli O. Hansen SA, et al. Eur J Health Econ. 2020 Feb;21(1):73-84. doi: 10.1007/s10198-019-01112-8. Epub 2019 Sep 11. Eur J Health Econ. 2020. PMID: 31512069 - Identification, synthesis and characterization of avanafil process impurities and determination by UPLC.
Zhao M, Wu X, Yu Z, Sun Y, Liu Z, Yuan J, Liu H, Jin Y. Zhao M, et al. RSC Adv. 2022 Mar 24;12(15):9256-9262. doi: 10.1039/d2ra01224c. eCollection 2022 Mar 21. RSC Adv. 2022. PMID: 35424898 Free PMC article. - Canadian Urological Association guideline: Erectile dysfunction.
Domes T, Najafabadi BT, Roberts M, Campbell J, Flannigan R, Bach P, Patel P, Langille G, Krakowsky Y, Violette PD. Domes T, et al. Can Urol Assoc J. 2021 Oct;15(10):310-322. doi: 10.5489/cuaj.7572. Can Urol Assoc J. 2021. PMID: 34665713 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical